Review: Prodrug Concept in Drug Design

Authors

  • Nada Abdelnasser Elsharif University of Benghazi

DOI:

https://doi.org/10.37591/(rrjops).v9i1.56

Abstract

        

 

Abstract

In the world of drug discovery and development, prodrugs have become a powerful method for improving biopharmaceutical, physicochemical or pharmacokinetic properties of pharmacologically active agents. The purpose of this review is to provide some types of prodrugs which are bioreversible derivatives of drug molecules that undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which can then exert the desired pharmacological effect. The target of prodrug design is to beat the undesirable drug properties, such as low target selectivity, low solubility in water or lipid membranes, chemical instability, irritation or pain after local administration, presystemic toxicity and metabolism. In this article, we focused on to describe the basic functional groups that are amenable to prodrug design and highlight the major applications of the prodrug strategy. Furthermore, the concepts of prodrug and the classifications of prodrugs will be offered in this article.

 

Keywords: Prodrug,derivatives of drug, drug-promoiety,antiviral, anticancer

 

Author Biography

  • Nada Abdelnasser Elsharif, University of Benghazi
    department of bioorganic chemistry

References

Albert, A. (1958). Chemical Aspects of Selective Toxicity. Nature, 182(4633), 421-423.

Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs--from Serendipity to Rational Design. Pharmacological Reviews, 63(3), 750-771.

Bertolini, A., Ferrari, A., Ottani, A., Guerzoni, S., Tacchi, R., & Leone, S. (2006). Paracetamol: New Vistas of an Old Drug. CNS Drug Reviews, 12(3-4), 250-275.

Stella, V. J., Borchardt, R. T., Hageman, M. J., Maag, H., Oliyai, R., & Tilley, J. W. (2007). Prodrugs Challenges and Rewards Part 1. New York (NY): Springer.

Wermuth, C. G. (2003). The practice of medicinal chemistry. Amsterdam: Academic Press.

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.

Jana, S., Mandlekar, S., & Marathe, P. (2010). Prodrug Design to Improve Pharmacokinetic and Drug Delivery Properties: Challenges to the Discovery Scientists. CMC Current Medicinal Chemistry, 17(32), 3874-3908.

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.

Mahato, R., Tai, W., & Cheng, K. (2011). Prodrugs for improving tumor targetability and efficiency. Advanced Drug Delivery Reviews, 63(8), 659-670.

Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs--from Serendipity to Rational Design. Pharmacological Reviews, 63(3), 750-771.

Han, H., & Amidon, G. L. (2000). Targeted prodrug design to optimize drug delivery. AAPS PharmSci, 2(1), 48-58.

Williams, R. O., Taft, D. R., & McConville, J. T. (2008). Advanced drug formulation design to optimize therapeutic outcomes. New York: Informa Healthcare.

Downloads

Published

2018-05-03

Issue

Vol. 9 No. 1 (2018)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.